Debelić M
Clinic for lung diseases, asthma and allergy Auguste-Viktoria- und Cecilienstift, Bad Lippspringe, Germany.
Allergol Immunopathol (Madr). 1992 May-Jun;20(3):97-100.
In a simple blind pilot study we have examined the protective effect of loratadine, a new H1 histamine receptor antagonist, against bronchoconstriction induced by histamine inhalation. Six patients with an episodic or continuing obstructive bronchial disease and proven bronchial hyperreactivity were submitted to two identical histamine challenges, first without premedication and then after three days' treatment with 10 mg loratadine daily. The mean FEV1 fall in the first test after histamine inhalation was 33% and in the second test after pretreatment with loratadine only 3.3% (p less than 0.01). Five out of six patients have shown complete protection against histamine-induced bronchoconstriction, in one patient the protection was partial. We conclude that loratadine effectively inhibits histamine-induced bronchoconstriction and could be useful in the prophylactic treatment of asthma and obstructive bronchitis.
在一项简单的盲法预试验中，我们研究了新型H1组胺受体拮抗剂氯雷他定对组胺吸入所致支气管收缩的保护作用。6例患有发作性或持续性阻塞性支气管疾病且已证实有支气管高反应性的患者接受了两次相同的组胺激发试验，第一次未进行预处理，第二次在每天服用10mg氯雷他定治疗三天后进行。组胺吸入后第一次试验中第一秒用力呼气量（FEV1）平均下降33%，而在氯雷他定预处理后的第二次试验中仅下降3.3%（p<0.01）。6例患者中有5例对组胺诱导的支气管收缩显示出完全保护作用，1例患者为部分保护作用。我们得出结论，氯雷他定可有效抑制组胺诱导的支气管收缩，可能对哮喘和阻塞性支气管炎的预防性治疗有用。
